Gene therapy developer Freeline Therapeutics priced an upsized offering at the top of its range following $275m in funding from investors including Novo.
Freeline Therapeutics, a UK-based gene therapy developer backed by pharmaceutical firm Novo, will raise almost $159m when it floats on the Nasdaq Global Select Market today.
The company increased the number of shares it is issuing from about 7.35 million to more than 8.82 million and priced them at the top of the initial public offering’s $16 to $18 range. Commercialisation firm Syncona is buying $24.3m of shares in the IPO, which values Freeline at about $620m.
Founded in…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
